Thursday, May 12, 2022 11:06:48 AM
From their 1st quarter report of 2 days ago -
"In March of 2022, the Company executed a Term Sheet with a third-party Equity Fund that will provide funding to enable the Company to return to reporting status, together with providing an Equity Line for additional working capital. As a condition for this capital injection, the Company has agreed to retain a PCAOB audit firm to enable the Company to transition from its current status of Alternative Reporting (unaudited financial statements) on OTC Markets to a fully reporting company with audited financial statements going forward."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168823365
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM